There is provided pharmaceutically-acceptable acid addition salts of compounds of formula I, ##STR00001## wherein R.sup.1 represents C.sub.1-2 alkyl substituted by one or more fluoro substituents; R.sup.2 represents C.sub.1-2 alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulan...

Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): ##STR00001## R1 is --(CH.sub.2).sub.nN.sup.+H- R3R4 X.sup.- or R1 is --(CH.sub.2).sub.nN.sup.+HR3R4 X.sup.- or --(CH.sub.2).sub.nNR3R4 when R2 is --N.sup.+HR6R7. R2 is --OR5, halogen, --NR6R7, --N.sup.+HR6R7 X.sup.-' sulphonic acid, nitro, --NR5COOR5, --NR5COR5 or --OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitr...

The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds.Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting o...

The present invention provides a sulfonium salt which can serve as a photo-acid-generator, the sulfonium salt not raising the problem of poor compatibility to a photoresist polymer having an acid-dissociable group. The sulfonium salt is represented by formula (1): ##STR00001## wherein R.sub.1 represents a linear or branched C2 to C9 divalent hydrocarbon group; each of R.sub.2 to R.sub.5 represents a hydrogen atom or a linear or branched C1 to C3 hydrocarbon group; each of R.sub.6 and R.sub.7 rep...

The invention relates to dialkylphosphinic salts of the formula (I) ##STR00001## where R.sup.1, R.sup.2 identical or different, are C.sub.1-C.sub.6-alkyl, linear or branched M is Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Li, Na, K and/or is a protonated nitrogen base; m is from 1 to 4; wherein the telomer content is from 0.01 to 6% by weight. The invention also relates to glare use in flame retardant compositions, and to flame-retardant polymer molding compositions and flame-retard...

Alkali metal carboxylate salt brines, such as cesium formate brine, are used in oil and gas drilling procedures. Contamination with chloride ions can be controlled by treatment with a silver salt solution, and removing silver chloride formed. High density brines can be obtained, suitable for re-use.

The present invention relates to tetrakisfluoroalkylborate salts, methods of producing same, and their use in electrolytes, batteries, capacitors, supercapacitors, and galvanic cells.

Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): ##STR1## R1 is --(CH.sub.2).sub.n N.sup.+ HR3R4 X.sup.- or R1 is --(CH.sub.2).sub.n N.sup.+ HR3R4 X.sup.- or --(CH.sub.2).sub.n NR3R4 when R2 is --N.sup.+ HR6R7. R2 is --OR5, halogen, --NR6R7, --N.sup.+ HR6R7 X.sup.- sulphonic acid, nitro, --NR5COOR5, --NR5COR5 or --OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitr...

This invention relates to [4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro-phthalazin- 1-yl]-acetic acid ethanolamine salt, pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to said mammals said salt and said compositions. This invention is also directed to combinations of said diethylamine salt with NHE-1 inhibitors, selective serotonin retuptake inhibitors (SSRIs), glycogen phosphorylase inhibitors (GPIs), sorbi...

The present invention relates to pharmaceutically acceptable salts of the compound of formula I or solvates of said salt in which the compound of formula I is as the (R)-enantiomer, the (S)-enantiomer or the racemate, ##STR1## a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.